Kim HD - Search Results

1

Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum β2-microglobulin Levels.

Kim HD, Cho H, Kim S, Lee K, Kang EH, Park JS, Park CS, Huh J, Ryu JS, Lee SW, Yoon DH, Kim SJ, Ko YH, Kim WS, Suh C. Kim HD, et al. Among authors: kim s, kim sj, kim ws. Cancer Res Treat. 2021 Jul;53(3):847-856. doi: 10.4143/crt.2020.1060. Epub 2020 Dec 17. Cancer Res Treat. 2021. PMID: 33332932 Free PMC article.

2

Tumor Volume Doubling Time as a Dynamic Prognostic Marker for Patients with Hepatocellular Carcinoma.

Kim JK, Kim HD, Jun MJ, Yun SC, Shim JH, Lee HC, Lee D, An J, Lim YS, Chung YH, Lee YS, Kim KM. Kim JK, et al. Among authors: kim km, kim hd. Dig Dis Sci. 2017 Oct;62(10):2923-2931. doi: 10.1007/s10620-017-4708-6. Epub 2017 Aug 16. Dig Dis Sci. 2017. PMID: 28815349

3

Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract Cancer.

Kim HD, Kim JH, Ryu YM, Kim D, Lee S, Shin J, Hong SM, Kim KH, Jung DH, Song GW, Hwang DW, Lee JH, Song KB, Ryoo BY, Jeong JH, Kim KP, Kim SY, Yoo C. Kim HD, et al. Among authors: kim d, kim kp, kim sy, kim kh, kim jh. Cancer Res Treat. 2021 Jan;53(1):162-171. doi: 10.4143/crt.2020.704. Epub 2020 Aug 31. Cancer Res Treat. 2021. PMID: 32878426 Free PMC article.

4

A prognostic index for extranodal marginal-zone lymphoma based on the mucosa-associated lymphoid tissue International Prognostic Index and serum β2-microglobulin levels.

Kim HD, Cho H, Jeong H, Bang K, Kim S, Lee K, Kang EH, Park JS, Park CS, Huh J, Ryu JS, Lee SW, Yoon DH, Oh SY, Suh C. Kim HD, et al. Among authors: kim s. Br J Haematol. 2021 Apr;193(2):307-315. doi: 10.1111/bjh.17222. Epub 2020 Nov 20. Br J Haematol. 2021. PMID: 33216979 Free article. Clinical Trial.

5

Use of Gemcitabine plus Carboplatin is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4-5.

Kim HD, Im HS, Kim JH, Jeong H, Yoon SK, Park I, Lee JL. Kim HD, et al. Among authors: kim jh. Cancer Res Treat. 2021 Oct;53(4):1166-1173. doi: 10.4143/crt.2021.091. Epub 2021 Mar 4. Cancer Res Treat. 2021. PMID: 33677847 Free PMC article.

6

Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis.

Casadei-Gardini A, Rimassa L, Rimini M, Yoo C, Ryoo BY, Lonardi S, Masi G, Kim HD, Vivaldi C, Ryu MH, Rizzato MD, Salani F, Bang Y, Pellino A, Catanese S, Burgio V, Cascinu S, Cucchetti A. Casadei-Gardini A, et al. Among authors: kim hd. J Cancer Res Clin Oncol. 2021 Dec;147(12):3665-3671. doi: 10.1007/s00432-021-03602-w. Epub 2021 Mar 20. J Cancer Res Clin Oncol. 2021. PMID: 33745079

7

The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery.

Jeong H, Park KJ, Lee Y, Kim HD, Kim JH, Yoon S, Hong B, Lee JL. Jeong H, et al. Among authors: kim hd, kim jh. Cancer Res Treat. 2022 Jan;54(1):226-233. doi: 10.4143/crt.2021.365. Epub 2021 May 6. Cancer Res Treat. 2022. PMID: 33957019 Free PMC article.

8

Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab.

Cho H, Ryu MH, Lee HE, Kim HD, Kang YK. Cho H, et al. Among authors: kim hd. Cancer Immunol Immunother. 2022 Apr;71(4):829-838. doi: 10.1007/s00262-021-03035-x. Epub 2021 Aug 22. Cancer Immunol Immunother. 2022. PMID: 34420059 Free PMC article.

9

Prognostic significance of serum β2-microglobulin levels in patients with peripheral T-cell lymphoma not otherwise specified.

Kim HD, Cho H, Sohn BS, Park CS, Huh J, Ryu JS, Lee SW, Yoon SE, Kim SJ, Ko YH, Kim WS, Suh C. Kim HD, et al. Among authors: kim sj, kim ws. Leuk Lymphoma. 2022 Jan;63(1):124-130. doi: 10.1080/10428194.2021.1971220. Epub 2021 Oct 26. Leuk Lymphoma. 2022. PMID: 34702115

10

Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis.

Kang S, Ryu MH, Bang YH, Kim HD, Lee HE, Kang YK. Kang S, et al. Among authors: kim hd. Cancer Res Treat. 2022 Oct;54(4):1167-1174. doi: 10.4143/crt.2021.1040. Epub 2021 Dec 6. Cancer Res Treat. 2022. PMID: 34883555 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,202 results

Search Page